Work

Quality of life response to BAROSTIM Therapy

Year: 2020

Type: article

Abstract: Background Patients with heart failure with reduced ejection fraction (HFrEF) have poor quality of life as measured by both physical and emotional dimensions. Purpose Evaluate the quality of life in subjects with and without baroreflex activation therapy (BAT) at six months. Methods In a multicenter randomized trial conducted in subjects with NYHA class II (recently III) or III HFrEF, left ventricular ejection fraction ≤35%, stable optimal guideline directed medical HF therapy (GDMT), no Class 1 indication for cardiac resynchronization therapy (CRT), and NT-proBNP<1600 pg/ml, a total of 264 subjects were randomized to BAROSTIM therapy plus GDMT (BAT group) or GDMT alone (Control group). Quality of life was measured at baseline and six months using the Minnesota Living with HF Questionnaire (MLWHF) and the EuroQol 5-Dimension Long (EQ-5D) tool. From the MLWHF questionnaire, both a physical and an emotional dimension was analyzed using subsets of the 21 questions. From the EQ-5D, the five individual dimensions and the overall health status (0–100, where 100 is best) was analyzed. Results Of the 264 randomized subjects, 120 BAT and 125 Control subjects had 6-month quality of life data. As shown in the table, treatment with BAT resulted in significant improvements in quality of life overall, as well as in the specific dimensions of the quality of life questionnaires, compared to the Control subjects. Conclusion Among subjects with symptomatic HFrEF, treatment with BAT resulted in significant improvement in quality of life at six months. Funding Acknowledgement Type of funding source: Private company. Main funding source(s): CVRx, Inc.

Source: European Heart Journal

DOI: 10.1093/ehjci/ehaa946.1120